Short Path to the Truth
Straightforward Path: "Follow the Money"
Straightforward Questions to Industry Executives and Insiders
- To Pharma:
- How much are you paying health insurer/PBMs?
- How are you paying them?
- Rebates vs. Fees vs. other ways?
- Are the “pharma fees” tied to brand drug “sticker” prices?
- What are you paying them these “pharma fees” for?
- What “support services” are the PBMs providing for these fees?
- How was the “fair” payment determined for these “services”, as is required by law?
- To Health Insurer/PBMs:
- How much of your brand drug revenues/profits come from pharma?
- From “rebates” vs. “pharma fees”?
- How are these “pharma fees” paid?
- Percent contracts tied to brand “sticker” prices?
- What are you getting these “pharma fees” for?
- What “support” work?
- How is it a “fair” price?
- In Part D, have these “pharma fees” been reported to the Government?
- How much reported?
- Where reported?
- How much of your brand drug revenues/profits come from pharma?
Readily Accessible Investigative Data
-
- National pharma/PBM “fee” contracts
- National Medicare Part D data
- Detailed Part D documentation requirements
- Clear Part D “pharma fee” legal requirements
Nothing subtle regarding the extreme taxpayer harm and alleged "kickbacks" in these vast Whistleblower cases
-
- 8-to-10-fold price increases
- Vast increases in U.S. Pharma brand sales driven ONLY by these massive price increases, as use by physicians and patients has sharply declined
- Massive “pharma fees” paid to health insurers/PBMs for doing a lot less legitimate work
- Massive and unprecedented Whistleblower alleged taxpayer harm
- In excess of $175 billion over the past decade-plus and ongoing
- The largest alleged healthcare Whistleblower case in U.S. history, by a wide margin
- Severe and escalating patient, family, business and taxpayer harm across the nation
- DOJ ADMITTED NOT DIRECTLY PURSUING THE CENTRAL KICKBACK AND OTHER KEY ALLEGATIONS IN ITS INVESTIGATION OF THESE WHISTLEBLOWER CASES